Sino Biological Inc.
1400 Liberty Ridge Drive
Suite 101
Wayne
PA
19087
United States
Website: http://www.sinobiological.com/
Email: marketing@sinobiological.com
About Sino Biological Inc.
Founded in 2007, Sino Biological is an international reagent supplier and service provider. The company specializes in recombinant protein production and antibody development. All of Sino Biological's products are independently developed and produced, including recombinant proteins, antibodies and cDNA clones. Sino Biological is the researchers’ one-stop technical services shop for the advanced technology platforms they need to make advancements. In addition, Sino Biological offer pharmaceutical companies and biotechnology firms pre-clinical production technology services for hundreds of monoclonal antibody drug candidates.
Sino Biological is dedicated to virology and infectious disease research. Its ProVir collection is the world’s largest viral antigen bank, carrying over 800 products from 350 strains of viruses. Sino Biological is the first company in the world to produce the SARS-CoV-2 viral antigens.
Sino Biological is an internationally recognized reagent supplier and contract research organization. Sino Biological's core technology platform is its in-house developed mammalian cell-based recombinant expression system. The system employs a range of proprietary reagents and processes, enabling high-efficient production of antigens and antibodies. The current catalog includes 10,000+ recombinant antigens, along with 2,000+ unique clones of monoclonal antibodies.
Sino Biological is dedicated to supporting SARS-COV-2 research. The company’s antibodies and antigens have been widely used to manufacture rapid antigen and antibody tests. Many of them have received the EUA from the FDA.
24 articles about Sino Biological Inc.
-
Therapeutic Potential of CD20 x CD3 Bispecific Antibodies
4/3/2024
On Monday, March 25th, 2024, the U.S. FDA declined approval for Regeneron’s Odronextamab for two forms of lymphoma due to concerns over the progress of ongoing confirmatory trials.
-
An ActRIIA Fusion Protein Got FDA Approved for PAH Treatment
3/28/2024
On March 26th, the US FDA granted approval for Merck’s WINREVAIR™ (sotatercept-csrk), marking a significant milestone in pulmonary arterial hypertension (PAH) treatment.
-
Sino Biological Announces Services Partnership with Rapid Novor
3/14/2024
Sino Biological, Inc., a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext, which provides biological research reagents and related technical contract research services, is pleased to announce the formation of a services partnership with Toronto, Canada-based Rapid Novor, Inc.
-
Sino Biological Announces the Opening of Its New US-Based Center for Bioprocessing
10/9/2023
Sino Biological, Inc. is pleased to announce the formal opening of its new Center for Bioprocessing (C4B) in Houston, Texas USA at Levit Green, adjacent to the world-renowned Texas Medical Center.
-
Sino Biological Announces Construction of Its New US-Based Center for Bioprocessing
11/21/2022
Sino Biological, Inc. is pleased to announce the formal signing of a lease with Hines and initiation of construction on its new Center for Bioprocessing at its Levit Green facility in Houston, Texas USA.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Sino Biological and Ainnocence Partner to Offer Next-Generation CRO Antibody Development Services
3/28/2022
Sino Biological, Inc.(“Sino Biological” or the “Company”), a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext (SZSE: 301047), which provides biological research reagents and related technical contract research services, is pleased to announce a CRO services partnership with Ainnocence, Inc. of San Jose, California.
-
Sino Biological and Ainnocence Partner to Offer Next-Generation Antibody Development CRO Services
3/24/2022
This empowers Ainnocence, using computer-based algorithms, to accurately design antibodies to be developed and manufactured by Sino Biological for clients worldwide. Financial terms were not disclosed.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Sino Biological Invests Over 200M RMB to Establish New Subsidiaries in Taizhou and Suzhou, China
3/15/2022
Sino Biological, Inc., a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext, which provides biological research reagents and related technical contract research services, is pleased to announce the formation of two new operationally-focused subsidiaries in China.
-
Sino Biological Invests Over 200M RMB to Establish New Subsidiaries in Taizhou and Suzhou, China.
3/14/2022
On September 13, 2021, the Board of Directors of Sino Biological reviewed and approved a proposal with Taizhou China Medical City Park to establish a wholly-owned subsidiary in the park.
-
Sino Biological Establishes New Location in Houston, Texas
12/31/2021
Sino Biological, Inc., a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext that provides biological research reagents and related technical contract research services, is pleased to announce its physical geographic expansion, adding a new location in Houston, Texas.
-
Sino Biological Deposits Recombinant Omicron Proteins and Antibodies to BEI Resources
12/31/2021
Sino Biological, Inc. (SZSE: 301047) has recently deposited reagents for the Omicron variant, including recombinant proteins to Spike and Nucleocapsid, and antibody products to BEI Resources, a central repository for reagents to support infectious disease research.
-
Sino Biological newly launched a panel of research reagents for SARS-CoV-2 Omicron variant
12/7/2021
Sino Biological, Inc. announced that it has launched a panel of research reagents for the newly identified Omicron variant of the SARS-COV-2 virus, which quickly raised concerns around the world because of the high number of mutations it carries, especially the 30-plus mutations on the Spike protein.
-
Sino Biological Newly Launched A Panel of Research Reagents for SARS-CoV-2 Omicron Variant (B.1.1.529)
12/6/2021
Sino Biological’s new Omicron product line includes recombinant Omicron Spike proteins (RBD, S1, and S-ECD trimer), monoclonal antibodies recognizing the Omicron Spike protein, and the Omicron pseudovirus assay CRO service.
-
Sino Biological, Inc. to be Featured on Worldwide Business with kathy ireland®
10/20/2021
Sino Biological, Inc (“Sino Biological” or the “Company”), a biotechnology company which provides biological research reagents and related technical contract research services, will be featured on Worldwide Business with kathy ireland®, airing on FOX Business Network, Bloomberg International and other outlets as sponsored content.
-
Sino Biological Announces Successful Closing of 4.98 Billion RMB Public Offering and Listing on the Shenzhen ChiNext Stock Exchange
8/16/2021
Sino Biological, Inc., a biotechnology company which provides biological research reagents and related technical contract research services, announced a successful listing on the Shenzhen Stock Exchange subsidiary ChiNext under the stock abbreviation Sino Biological and stock code 301047.
-
Qiming's Portfolio Company Sino Biological Lists on Shenzhen's ChiNext Market
8/16/2021
Qiming Venture Partners' portfolio company Sino Biological on August 16th listed on Shenzhen's ChiNext Market.
-
Sino Biological, Inc. Announces Successful Closing of 4.98 Billion RMB Public Offering and Listing on the Shenzhen ChiNext Stock Exchange
8/16/2021
Sino Biological, Inc. announced a successful listing on the Shenzhen Stock Exchange subsidiary ChiNext under the stock abbreviation Sino Biological and stock code 301047.
-
Sponsored | Employing Immunologic Testing to Expedite Detection and Control the Spread of COVID-19
3/26/2021
To support the development of immunodiagnostic assay, Sino Biological has successfully generated biologically active and stable Spike and NP proteins of SARS-CoV-2.